2Field KM,Michael M.Part II:Liver function in oncology: towards safer chemotherapy use[].The Lancet Oncology.2008
3Jeronte A,Jean Marie T,Marine GG,et al.Conflfination of topotean and oxliplatin in inoperable hepatocellular cancer patients[].Ant J Clin oncol.2002
4Nahum MS,Francisco VF,Daniel ZV,et al.Sorafenib, a systemic therapy for hepatocellular carcinoma[].Annals of Hepatology.2008
5Cheng AL,Kang YK,Chen Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacifi c region with advanced hepatocellular carcinoma:a phaseⅢrandomised,double-blind,placebo-controlled trial[].The Lancet Oncology.2009
6ThomasMB,Dutta A,Brown T,et al.A phaseⅡopen-label study of OSI-774 (NSC 718781) in unresectable hepatocellular carcinoma[].Proceedings of the American Society of Clinical Oncology.2005
7Ishii Y,Sakamoto T,Ito R,et al.Anti-angiogenic Therapy on Hepatocellular Carcinoma Development and Progression[].Journal of Surgical Research.2008
8Lencioni R,Crocetti L,Petruzzi P,et al.Doxorubicin -eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma:A pilot clinical study[].Journal of Hepatology.2008
9Yang T,Lin Y,Chen J,et al.Phase Ⅱ study of gemcitabine in patients with advanced hepatocellular carcinoma[].Cancer.2000
10Eleutherakis-Papaiakovou V,Bamias A,Dimopoulos MA.Thalidomide in cancer medicine[].Annals of Oncology.2004
二级参考文献9
1Valle JW,Dangoor A,Beech J,et al.Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin(PLD):results of a phase Ⅱ study.Br J Cancer,2005,92:628-630.
2Yehuda Z,Manal M,Alvaro A,et al.Oral capecitabine for the treatment of hepatocellular carcinoma,cholangiocarcinoma,and gallbladder carcinoma.Cancer,2004,101:578-586.
3Campbell JS,Hughes SD,Gilbertson DG,et al.Platelet-derived growth factor C induces liver fibrosis,steatosis,and hepatocellular carcinoma.Proc Natl Acad Sci U S A,2005,102:3389-3394.
4Matsuo M,Sakurai H,Saiki I.ZD1839,a selective epidermal growth factor receptor tyrosine kinase inhibitor,shows antimetastatic activity using a hepatocellular carcinoma model.Mol Cancer Ther,2003,2:557-561.
5Philip PA,Mahoney M,Thomas J,et al.Phase Ⅱ Trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer.Presented at 2004 ASCO Annual Meeting Proceedings,New Orleans,LA,2004.
6Zhu AX,Sahani D,Norden-Zfoni N,et al.A Phase Ⅱ Study of gemcitabine,Oxaliplatin in Combination with bevacizumab (GEMOX-B) in patients with Hepatocellular Carcinoma.Presented at 2005 American Society of Clinical Oncology Annual Meeting,Orlando,FL,2005.
7Hegewisch-Becker S,Sterneck M,Schubert U,et al.Phase Ⅰ/Ⅱ trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC).Presented at 2004 ASCO Annual Meeting,New Orleans,LA,2004.
8Nemunaitis J,Khuri F,Ganly Ⅰ,et al.Phase Ⅱ trial of intratumoral administration of ONYX-015,a replication-selective adenovirus,in patients with refractory head and neck cancer.J Clin Oncol,2001,19:289-298.
9Monvoisin A,Bisson C,Si-Tayeb K,et al.Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells.Int J Cancer,2002,97:157-162.
